GNFT מכפיל P/S עתידי Genfit SA

The forward P/S of Genfit S.A. (GNFT) on GURU.Markets demonstrates that valuation depends on the success of liver therapy programs, where the value 5.40 describes the current level. Growth metrics are based on robotic molecule design, although trials require physicians. Meanwhile, a revenue deficit is leading to the depletion of reserves and a search for external capital to cover R&D costs.

A steady stream of royalties from the sale of a liver treatment drug provides Genfit S.A. (GNFT) with a financial foundation, although R&D expenses for new drugs make the valuation critical. By analyzing the company's modeled P/S, an investor can see the ratio of current market capitalization to expected annual revenue, which allows for an assessment of market optimism regarding future earnings and the risk of overpaying for the asset.